Why GlaxoSmithKline plc And AstraZeneca plc Are The Best Bargains In The FTSE 100!

GlaxoSmithKline plc (LON: GSK) and AstraZeneca plc (LON: AZN) are two of the most undervalued stocks in the FTSE 100 (INDEXFTSE: UKX).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

It has been a rough year for GlaxoSmithKline (LSE: GSK) and AstraZeneca’s (LSE: AZN) investors. 

After a flurry of bid activity and rumours last year, it been a relatively quiet year for both companies as they double-down on their strategies to boost sales. 

However, while these two pharma giants are working flat out to return to growth, the market is losing patience. Since the end of March, Astra and Glaxo’s shares have declined by 17.4% and 18.3% respectively, excluding dividends. Over the same period, the FTSE 100 has lost 8.3%. 

But after these declines, Glaxo and Astra now look to me to be the most undervalued companies in the UK’s leading index!

Slow and steady

Claiming that Glaxo and Astra are the two most undervalued companies in the FTSE 100 is a bold statement to make. Nonetheless, these two groups exhibit all the traits of classic contrarian value investments. 

And when compared to some of the other FTSE 100 companies that have underperformed this year, the likes of HSBCShellBHP and Glencore, the two biotechs look to be vastly superior.

For example, Glaxo and Astra are still highly profitable. Glaxo’s operating margin was 50.5% for 2014 and Astra’s is expected to report a net profit margin of 22.4% for 2015. 

What’s more, the two biotechs have pricing power, and, as a result, a certain degree of control over future profits. HSBC, Shell, BHP and Glencore are all subject to market forces when it comes to product pricing. 

Then there are Glaxo and Astra’s R&D initiatives to consider. 

Research and development 

Philip Arthur Fisher is widely regarded as one of the best growth investors of the last century. His book Common Stocks and Uncommon Profits is still in print today nearly six decades after it was published. 

Fisher’s strategy was simple; buy undervalued growth stocks and hold for the long term. Now, trying to find tomorrow’s winners today is difficult, but Fisher was able to succeed by hunting out the companies that were spending heavily on R&D. In Fisher’s own words: 

“If the company is deliberately and consistently developing new sources of earning power…the price-earnings ratio five or ten years in the future is rather sure to be as much above that of the average stock as it is today…This is why some of the stocks that at first glance appear highest priced may, upon analysis, be the biggest bargains.”

Firms that continually invest for future growth will, over the long-term, achieve better returns for investors than those companies that are focused on boosting short-term profits. 

Glaxo and Astra are both investing heavily for the future. 

Specifically, Glaxo has 258 new products under development more than any other big pharma group. Around 40 of these products are in advanced clinical trials and management expects at least half of its drugs currently under development will be on the market by 2020.

Astra has 222 new products in its treatment pipeline, several of which are expected to be blockbusters. City analysts believe that these new blockbuster treatments will produce sales for the group of around $4bn per annum by 2018. 

The bottom line 

So overall, Glaxo and Astra may have underperformed this year, but explosive growth could be just around the corner.

Investors will be paid to wait for this recovery as Astra currently supports an attractive dividend yield of 4.5% and Glaxo yields 6.3%.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Rupert Hargreaves owns shares of AstraZeneca and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline and HSBC. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »